目的 研究蘇黃止咳膠囊聯(lián)合丙酸倍氯米松氣霧劑治療慢性支氣管炎急性發(fā)作期的臨床療效。方法 選取2018年4月-2019年4月在平煤神馬醫(yī)療集團(tuán)總醫(yī)院治療的140例慢性支氣管炎急性發(fā)作期患者，所有患者隨機分為對照組和治療組，每組各70例。對照組患者給予丙酸倍氯米松氣霧劑，2撳/鼻孔，2次/d。治療組在對照組基礎(chǔ)上給予蘇黃止咳膠囊，3粒/次，3次/d。兩組患者持續(xù)治療14 d。觀察兩組患者臨床療效，比較兩組的臨床癥狀緩解時間、血清炎性指標(biāo)水平、肺功能指標(biāo)、支氣管炎的嚴(yán)重程度（BSS）評分。結(jié)果 治療后，治療組總有效率（95.71%）顯著高于對照組（84.29%）（P<0.05）。治療后，治療組咳痰、咳嗽、發(fā)熱、肺部啰音消退時間明顯短于對照組（P<0.05）。治療后，兩組血清白細(xì)胞介素（IL）-8、腫瘤壞死因子（TNF）-α、超敏C反應(yīng)蛋白（hs-CRP）水平顯著降低（P<0.05）；并且治療組血清炎性因子水平降低較多（P<0.05）。治療后，兩組患者第1秒用力呼氣容積（FEV₁）、峰值呼氣流速（PEF）和FEV₁/用力肺活量（FVC）顯著升高（P<0.05），且治療組肺功能指標(biāo)升高較多（P<0.05）。治療后，兩組BSS評分顯著降低（P<0.05）；并且治療組BSS評分降低較多（P<0.05）。結(jié)論 蘇黃止咳膠囊聯(lián)合丙酸倍氯米松氣霧劑治療慢性支氣管炎急性發(fā)作期具有較好的臨床療效，能夠改善患者肺功能和臨床癥狀，降低血清炎性因子水平，值得在臨床上推廣應(yīng)用。

Objective To study the efficacy of Suhuang Zhike Capsules combined with beclomethasone propionate in treatment of acute episode of chronic bronchitis. Methods Patients (140 cases) with acute episode of chronic bronchitis in Pingmei Shenma Medical Group General Hospital from April 2018 to April 2019 were randomly divided into control and treatment groups, and each group had 70 cases. Patients in the control group were given Beclometasone Dipropionate Aerosol, 2 press/nostril, twice daily. Patients in the treatment group were po administered with Suhuang Zhike Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and clinical symptom relief time, serum level of inflammatory indexes, pulmonary function index, and BSS score in two groups were compared. Results After treatment, the total effective rate of the treatment group (95.71%) was significantly higher than that of the control group (84.29%) (P<0.05). After treatment, resolution times of expectoration, cough, fever, and lung rales in the treatment group were significantly shorter than those in the control group (P<0.05). After treatment, the levels of IL-8, TNF-α, and hs-CRP in two groups were significantly decreased (P<0.05); and the indexes in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, FEV₁, PEF, and FEV₁/FVC in two groups were significantly increased (P<0.05); and the indexes in the treatment group were significantly higher than those in the control group (P<0.05). Conclusion Suhuang Zhike Capsules combined with beclomethasone propionate has clinical curative effect in treatment of acute episode of chronic bronchitis, can improve pulmonary function and clinical symptoms of patients, reduce the serum level of inflammatory factors, which is worthy of clinical application.

R974